<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634647</url>
  </required_header>
  <id_info>
    <org_study_id>080074</org_study_id>
    <secondary_id>08-C-0074</secondary_id>
    <nct_id>NCT00634647</nct_id>
  </id_info>
  <brief_title>Satraplatin and Prednisone to Treat Prostate Cancer</brief_title>
  <official_title>A Phase II Study of Satraplatin and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Satraplatin is an experimental drug that may be of benefit to patients with prostate cancer.

      Prednisone is approved for treating prostate cancer.

      The gene excision repair cross-complementing rodent repair deficiency complementation group 1
      (ERCC1) helps repair cell damage caused by satraplatin. It is possible that patients who have
      a variant of this gene will not benefit from treatment with satraplatin because the drug will
      not be able to damage the cancer cells effectively.

      Objectives:

      To determine if satraplatin may help treat prostate cancer in patients with certain variants
      of the ERCC1 gene.

      Eligibility:

      Patients with advanced androgen-independent prostate cancer whose disease has not responded
      to hormonal therapy or at least one type of chemotherapy and whose x-rays, scans or other
      tests have shown their cancer to be spreading.

      Design:

      Participants have a blood test to determine if they have a variant of the ERCC1 gene.

      Participants take satraplatin by mouth every day for 5 consecutive days out of every 35 days
      and prednisone by mouth every day. These 35-day treatment cycles may continue for 6 months or
      longer, depending on the benefits and side effects of the treatment.

      During the treatment period, patients undergo the following tests and procedures:

        -  Blood tests on days 1 of the treatment cycle.

        -  Weekly blood draws for the first 3 treatment cycles.

        -  Imaging studies (e.g., bone scans, computed tomography (CT) scans) every two cycles to
           determine the response to treatment.

        -  Surgical or medical suppression of testosterone in patients whose cancer cells continue
           to grow due to exposure to the hormone....
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

        -  Satraplatin is an oral, third-generation platinum analog that has recently been shown to
           increase prostatic specific antigen (PSA) decline rates and progression-free survival in
           hormone-resistant prostate cancer.

        -  Satraplatin acts by binding to deoxyribonucleic acid (DNA) forming intra- and
           interstrand cross links (DNA adducts), resulting in cell-cycle arrest in G2 phase and
           eventual apoptosis. One of the mechanisms that bring about resistance to platinum-based
           chemotherapy is removal of the platinum-DNA adducts by DNA repair pathways, called
           nucleotide excision repair (NER) and base excision repair (BER) pathways.

        -  Polymorphisms in the DNA repair genes causing impaired NER and BER capability has
           recently been shown in some cancers, including head and neck squamous cell carcinoma,
           non-small cell lung carcinoma, and ovarian carcinoma to predict better treatment outcome
           and response to platinum treatment.

      Objectives:

        -  Primary objective of this single arm study is to determine if the presence of ERCC1
           variant gene polymorphism which is involved with DNA damage repair may be associated
           with an impact on the progression-free survival of patients with metastatic prostate
           cancer.

        -  Secondary objectives of this study includes demonstration of biologic effect by the drug
           satraplatin in the patient and in the tumor whenever possible, by obtaining tissue
           biopsy and white blood cell collections, to determine correlation of biologic or
           clinical effects with PSA progression, evaluate correlations between genotype
           expression, repair pathways and clinical events, and obtain laboratory correlates which
           will include pharmacogenetic analysis of prostate cancer patients with genotyping using
           Polymerase chain reaction (PCR) followed by either restriction fragment length
           polymorphism or direct sequencing to genotype single nucleotide polymorphisms of ERCC1,
           x-ray repair cross-complementing protein 1 (XRCC1), and poly (ADP-ribose) polymerase 1
           (PARP1).

      Eligibility:

        -  Patients with metastatic androgen-independent prostate cancer.

        -  Had docetaxel-based chemotherapy, but no more than 1 previous cytotoxic chemotherapy
           line.

        -  Good organ function.

      Design:

        -  Phase II trial with single stage design and a planned accrual of 66 patients.

        -  Progression-free survival will be determined using a Fisher's exact test.

        -  Will treat all enrolled patients with oral satraplatin 80 mg/m^2 dose on days 1-5 of
           every 35-days cycle plus Prednisone 5 mg twice daily every 35 days.

        -  Genotyping will be performed after the first 20 patients to determine if the proportion
           for wild-type ERCC1 and variants follow a 20:80 split.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival.</measure>
    <time_frame>15 months</time_frame>
    <description>Time between the start of therapy and progression. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progressive Disease is at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>6/4/08/ to 4/1/12</time_frame>
    <description>Here is the number of participants with adverse events. For a detailed of list of adverse events, see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Genetic Polymorphism</condition>
  <arm_group>
    <arm_group_label>Satraplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Satraplatin</intervention_name>
    <description>80 mg/m^2 days 1-5 of every 35 day cycle</description>
    <arm_group_label>Satraplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>5 mg twice daily every 35 days</description>
    <arm_group_label>Satraplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        A. Patients must have histopathological confirmation of prostate cancer by the Laboratory
        of Pathology of the National Cancer Institute (NCI) or Pathology Department of the National
        Naval Medical Center or Walter Reed Army Medical Center prior to entering this study.
        Patients whose pathology specimens are not available may be enrolled in the trial if the
        patient has a clinical course consistent with prostate cancer and available documentation
        from an outside pathology laboratory of the diagnosis. In cases where original tissue
        blocks or archival biopsy material is available, all efforts should be made to have the
        material forwarded to the research team for use in correlative studies.

        B. Patients must have metastatic progressive androgen-independent prostate cancer. There
        must be radiographic evidence of disease (by computed tomography (CT) scan or bone scan)
        after primary treatment that has continued to progress despite hormonal agents. Progression
        requires that a measurable lesion is expanding, new lesions have appeared, and/or that
        prostatic specific antigen (PSA) is continuing to rise on successive measurements. Patients
        must have progressive disease after receiving 1 prior docetaxel-based cytotoxic
        chemotherapy. Patients on flutamide for the prior 6 months must have disease progression at
        least 4 weeks after withdrawal. Patients on bicalutamide or nilutamide must have
        progression at least 6 weeks after withdrawal.

        C. Patients may only have received 1 prior cytotoxic chemotherapy. For the purpose of this
        study, multiple courses of a taxane-based regimen may count as a single regimen. Multiple
        courses of a non-taxane agent or a combination chemotherapy regimen, administered in a
        similar fashion may count as a single regimen.

        D. Patients must have a life expectancy of more than 3 months.

        E. Patients must have a performance status of 0 to 2 according to the Eastern Cooperative
        Oncology Group (ECOG) criteria.

        F. Patients must have adequate organ function as defined below:

        Leukocytes greater than or equal to 3,000/microl.

        Absolute Neutrophil Count greater than or equal to 1,500/microl.

        Platelets greater than or equal to 100,000/microl.

        Total bilirubin less than or equal to 1.5 times institutional upper limits of normal
        (Except patients with Gilbert's disease who may proceed despite elevated total bilirubin).

        Aspartate aminotransferase (AST)serum glutamic oxaloacetic transaminase(SGOT) and alanine
        aminotransferase (ALT)serum glutamic pyruvic transaminase (SGPT) less than or equal to 2.5
        times institutional upper limit of normal

        Creatinine less than or equal to 1.5 times institutional upper limits of normal.

        OR

        Creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with
        creatinine levels above institutional normal.

        G. Patients must have recovered from any acute toxicity related to prior therapy, including
        surgery. Toxicity should be &lt;= grade 1 or returned to baseline.

        H. Hormonal profile: all patients who have not undergone bilateral surgical castration must
        continue suppression of testosterone production by appropriate usage of gonadotropin
        releasing hormone (GnRH) agonists.

        I. Patients must not have any ongoing malignancies requiring active therapy.

        J. Patients must be able to understand and sign an informed consent form.

        K. Concurrent use of bisphosphonates will be allowed if patients have previously been on
        it; if patients are not on bisphosphonates at the time of study enrollment, bisphosphonates
        may be started at cycle 2.

        L. Patients who require hematopoietic growth factor support (e.g. epogen, darbepoetin), but
        not myeloid growth factors (except after cycle 1 day 1 if clinically indicated),
        non-steroidal anti-inflammatory drug (NSAIDs), and other maintenance medications prior to
        study entry will be allowed to continue their supportive therapies.

        M. Results from embryo-fetal development indicated that satraplatin should be considered a
        teratogen in women of childbearing potential and hazardous in respect to spermatogenesis
        for men. For this reason, men must agree to use adequate contraception (abstinence;
        hormonal or barrier method of birth control) prior to study entry and for the duration of
        study participation.

        N. Patients must be able to swallow capsules.

        O. Patients on chronic stable steroids (equivalent to no more than 10 mg of prednisone
        daily dose) used for non-cancer treatment may be allowed on study.

        EXCLUSION CRITERIA:

        A. Patients who have had prior treatment with satraplatin or other platinum containing
        compounds will be excluded.

        B. Patients may not be receiving any other investigational agents.

        C. Patients with known active brain metastases are excluded from this clinical trial
        because of their poor prognosis and because they often develop progressive neurologic
        dysfunction that would confound the evaluation of neurologic and other adverse events.

        D. History of allergic reactions attributed to compounds of similar chemical or biologic
        composition to satraplatin or prednisone.

        E. Uncontrolled intercurrent illness including, but not limited to ongoing or active
        serious infection, symptomatic congestive heart failure, unstable angina pectoris, or
        psychiatric illness/social situations that would limit patient compliance with study
        requirements.

        F. Prior radiation therapy to greater than 30 percent of the bone marrow, or who have
        received strontium-89, rhenium-186, or rhenium-188 will be excluded from this trial.
        Patients who have received prior radiotherapy must have recovered from acute toxicity due
        to radiation. Patients who have received samarium-153 are eligible for the study because
        samarium has a significantly reduced half-life compared to aforementioned isotopes.

        G. Patients with immune deficiency are at increased risk of lethal infections when treated
        with marrow-suppressive therapy. Therefore, human immunodeficiency virus (HIV)-positive
        patients are excluded from the study.

        H. Patients with a history of major gastrointestinal surgery or pathology likely to
        influence absorption of oral medications, like bypass surgeries, Whipple's procedure, or
        any surgery that would impair reliable absorption of oral drugs.

        I. Patients with a disease where corticosteroids are contraindicated, e.g. active gastric
        or duodenal ulcer, or poorly controlled insulin dependent diabetes. Patients with
        well-controlled insulin-dependent diabetes mellitus may be considered, providing they
        understand their glucose levels will increase, and their insulin dose will require
        adjusting.

        J. Because no dosing or adverse event data are currently available on the use of
        satraplatin in patients less than 18 years of age, children are excluded from this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William L Dahut, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology and Hematology</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2008-C-0074.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000 Jun;163(6):1632-42. Review.</citation>
    <PMID>10799151</PMID>
  </reference>
  <reference>
    <citation>Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, Leibel SA, Venkatraman ES. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005 Feb 1;23(4):826-31.</citation>
    <PMID>15681527</PMID>
  </reference>
  <reference>
    <citation>Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998 Dec;160(6 Pt 2):2428-34.</citation>
    <PMID>9817397</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <results_first_submitted>February 27, 2013</results_first_submitted>
  <results_first_submitted_qc>February 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2013</results_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>William Dahut Jr., M.D.</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Gene Polymorphisms</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Satraplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Satraplatin</title>
          <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>death on study</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>declined to participate before treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Satraplatin</title>
          <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.83" spread="9.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival.</title>
        <description>Time between the start of therapy and progression. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progressive Disease is at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>15 months</time_frame>
        <population>21 out of 24 participants was analyzed because three patients were taken off study before progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin</title>
            <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival.</title>
          <description>Time between the start of therapy and progression. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Progressive Disease is at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>21 out of 24 participants was analyzed because three patients were taken off study before progression.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="2.3" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Here is the number of participants with adverse events. For a detailed of list of adverse events, see the adverse event module.</description>
        <time_frame>6/4/08/ to 4/1/12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Satraplatin</title>
            <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Here is the number of participants with adverse events. For a detailed of list of adverse events, see the adverse event module.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Satraplatin</title>
          <description>satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Other (septic shock)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="51" subjects_affected="18" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual-Other, visual field deficit (blind spot)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dental: periodontal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dental: teeth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other (pain intermittent diarrhea)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis (clinical exam)::oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain-abdomen NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>(in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain -Other,intermittent LE pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder (urinary)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder tract NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT/SGPT (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>AST/SGOT (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-Other, muscle cramping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain::Back</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain::Extremity-limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neuropathy:sensory</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary retention (including neurogenic bladder)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pain::Pelvis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify)</sub_title>
                <description>left ear &quot;blk lesion&quot; papular flat; rashes</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hair loss/alopecia (scalp or body)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Dahut</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-435-8183</phone>
      <email>dahutw@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

